Our Mission Is To Develop Therapies that Are:
Tough on Cancer,
Gentle on Patients.
Technology and Knowledge Converge
The Vanquish System utilizes the growing body of clinical data, improved prostate imaging and biopsy technologies, and patient advocacy to offer a new option for patients.
One in 8 men will be diagnosed with prostate cancer in their lifetime. The majority of men with localized, low-to-intermediate risk prostate cancer will be presented with one of two options: whole prostate gland removal or radiation, which have a high potential for long-term side effects, or active surveillance, which allows them to maintain their quality of life.
Disclosure: The Vanquish® Water Vapor Ablation System has been cleared as a tool for the thermal ablation of targeted prostate tissue via a transurethral approach. The FDA has not evaluated the Vanquish System for the treatment of any disease, including prostate cancer, or evaluated the Vanquish System for any long-term prostate cancer treatment outcomes.
The Vanquish System provides targeted ablation of prostate tissue in any location in the prostate.
Clinical Evidence.
VAPOR 2 (n=110)
Clinical Data and Patient Satisfaction Results:
91%
clearance of targeted MRI visible ≥GG2 disease following a single treatment
2.7%
≥ Grade 2 urinary incontinence
No device related
serious adverse events
Low rates of
erectile dysfunction
93%
of patients were extremely satisfied or satisfied with the Vanquish procedure at 12 months (n=107)
94%
of the patients believed that the Vanquish procedure was a good decision (n=107)
Minimal to no pain
Most patient reported no pain.
Follow Us
Federal law (USA) restricts this device to sale by or on the order of a physician.
Refer to the device User Manual for a list of contraindications, warnings, and cautions.
Training: Do not operate the Vanquish System without completing Francis Medical-provided physician training. Untrained operation of the device may lead to improper use. Improper use can result in patient injury or equipment malfunction.